T-cell Prolymphocytic Leukemia.
![Thumbnail](/bitstream/handle/internal/969/TPLL_AS_CD_resub.pdf.jpg?sequence=8&isAllowed=y)
View/ Open
Date
2017-04-01ICR Author
Author
Sud, A
Dearden, C
Type
Journal Article
Metadata
Show full item recordAbstract
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive T-cell malignancy. T-PLL can be distinguished from other lymphoid diseases by the evaluation and integration of clinical features, morphology, immunophenotyping, cytogenetics, and molecular features. The current therapeutic approach relies on immunotherapy followed by a hematopoietic stem cell transplant in selected cases. Clinical outcomes are generally poor, although insights from genomic and molecular studies may increase our understanding of this disease, with the promise of additional effective therapeutic options.
Collections
Subject
Disease-Free Survival
Immunotherapy
Hematopoietic Stem Cell Transplantation
Survival Rate
Leukemia, Prolymphocytic, T-Cell
Allografts
Language
eng
Date accepted
2016-08-12
License start date
2017-04
Citation
Hematology/oncology clinics of North America, 2017, 31 (2), pp. 273 - 283
Publisher
W B SAUNDERS CO-ELSEVIER INC